Alembic Pharmaceuticals Limited (NSE:APLLTD)

Alembic Pharmaceuticals Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul 18, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	202,735	182,755	193,575	97,564	145,771	189,674
Market Cap Growth	-5.59%	-5.59%	98.41%	-33.07%	-23.15%	88.33%
Enterprise Value	214,461	192,124	200,785	104,548	151,109	193,139
Last Close Price	1031.40	929.75	973.82	485.46	714.30	916.00
PE Ratio	34.75	31.33	31.43	28.53	27.98	16.54
Forward PE	28.43	25.37	28.71	19.15	19.76	18.14
PS Ratio	3.04	2.74	3.11	1.73	2.75	3.52
PB Ratio	3.91	3.52	4.02	2.23	2.78	3.74
P/TBV Ratio	3.91	3.52	4.02	2.23	2.87	4.00
P/FCF Ratio	-	-	40.69	34.78	115.04	23.60
P/OCF Ratio	230.46	207.75	24.10	13.48	26.39	12.96
PEG Ratio	1.24	1.13	1.09	1.89	-	1.24
EV/Sales Ratio	3.21	2.88	3.22	1.85	2.85	3.58
EV/EBITDA Ratio	21.25	19.42	21.97	15.02	17.60	13.17
EV/EBIT Ratio	29.35	26.33	30.39	23.88	25.72	14.89
EV/FCF Ratio	-45.09	-	42.21	37.27	119.26	24.03
Debt / Equity Ratio	0.24	0.24	0.11	0.17	0.14	0.12
Debt / EBITDA Ratio	1.25	1.25	0.55	1.01	0.82	0.39
Debt / FCF Ratio	-	-	1.08	2.57	5.66	0.73
Asset Turnover	0.94	0.94	0.99	0.85	0.77	0.85
Inventory Turnover	0.96	0.96	1.15	1.15	0.97	1.00
Quick Ratio	0.62	0.62	0.82	0.74	0.52	0.51
Current Ratio	1.70	1.70	2.12	1.78	1.67	2.07
Return on Equity (ROE)	11.63%	11.63%	13.40%	7.12%	10.11%	27.77%
Return on Assets (ROA)	6.42%	6.42%	6.54%	4.11%	5.31%	12.77%
Return on Capital (ROIC)	7.75%	7.75%	7.92%	4.95%	6.33%	15.19%
Return on Capital Employed (ROCE)	13.60%	13.60%	13.20%	9.60%	10.90%	23.90%
Earnings Yield	2.88%	3.19%	3.18%	3.50%	3.57%	6.04%
FCF Yield	-2.35%	-2.60%	2.46%	2.88%	0.87%	4.24%
Dividend Yield	1.07%	1.18%	1.13%	1.65%	1.40%	1.53%
Payout Ratio	37.06%	37.06%	25.54%	57.48%	52.83%	-
Buyback Yield / Dilution	-	-	-	-	-1.46%	-2.77%
Total Shareholder Return	1.07%	1.18%	1.13%	1.65%	-0.06%	-1.24%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.